ARVC51
FAMRCi011-A
General
Cell Line |
|
| hPSCreg name | FAMRCi011-A |
| Cite as: | FAMRCi011-A (RRID:CVCL_B5H4) |
| Alternative name(s) |
ARVC51
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
FAMRCi011-B (ARVC51b) Donor's gene variants: FLNC Donor diseases: Inherited arrhythmogenic cardiomyopathy UKKi035-A (NP0139-A, NP0139-3E) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-B (NP0139-B, NP0139-6C) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-C (NP0139-C, NP0139-24D) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy SCVIi073-A (SCVIi574C2) Donor's gene variants: titin, BAG cochaperone 3, BAG cochaperone 3 Donor diseases: Dilated Cardiomyopathy SCVIi074-A (SCVIi599C1) Donor's gene variants: BAG cochaperone 3 Donor diseases: Hypertrophic Cardiomyopathy |
| Last update | 1st March 2024 |
| User feedback | |
Provider |
|
| Generator | Federal Almazov North-West Medical Research Centre (FAMRC) |
| Owner | Institute of Molecular Biology and Genetics |
| Distributors | |
| Derivation country | Russia |
External Databases |
|
| BioSamples | SAMEA9687267 |
| Cellosaurus | CVCL_B5H4 |
| Wikidata | Q110432800 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
46,XY
Karyotyping method:
Array CGH
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA9687268 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | Local ethical committee of Almazov National Medical Research Centre |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Local ethical committee of Almazov National Medical Research Centre |
| Approval number | №13/19.06.2014 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
ReleSR
|
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY
Passage number: 10
Karyotyping method:
Array CGH
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.